Category
Covering medical studies
-
Racial disparities seen in Alzheimer’s disease diagnoses
Black participants in Alzheimer’s disease research studies were 35% less likely to be diagnosed with Alzheimer’s and related dementias than…
-
Study shows that social contact intervention may reduce mental health stigma, suggests solutions journalism ideas
One of the biggest barriers to seeking mental health care is stigma. While I can point to some studies that show this all over the world, the…
-
Everything journalists need to know about Robert Califf, the newly nominated FDA commissioner
President Joe Biden nominated cardiologist Robert Califf for Food and Drug Administration (FDA) commissioner to replace Janet Woodcock, who has…
-
Words matter: How you use them when covering mental illness can reduce — or increase stigma
Journalists already know it’s important to be thoughtful and respectful when including patient stories in our reporting. Where it gets…
-
Rural liver cancer rates on the rise: How journalists can raise awareness
Though liver cancer rates have historically been lower in rural areas, they have recently increased and urban rates have started…
-
American Journal of Public Health dedicates issue to health inequities and justice
Health inequalities have long been a concern in medicine. A robust evidence base has been growing for decades regarding social…
-
How I Did It: Marilynn Marchione concludes an impressive career in medical writing
Marilynn Marchione was the Associated Press’s chief medical writer for the last 10 years of her long career in journalism.…
-
Science center’s principles offer guidance to reporters covering complicated COVID-19 issues
While most AHCJ members have been writing about health for a while, the COVID-19 pandemic suddenly turned nearly every other…
-
Wednesday NIH webinar on women and alcohol highlights obscured problem
While recent headlines have pointed out the disastrous rise in opioid use during the pandemic, less attention has focused on…
-
Another Alzheimer’s treatment takes a different route than the rest
Editor’s Note: This is part 2 of a two-part package on the pipeline for Alzheimer’s disease drugs. Check out part…
